Background About half of heart failure (HF) patients, while having preserved left ventricular function, suffer from diastolic dysfunction (so-called HFpEF). No specific therapeutics are available for HFpEF in contrast to HF where reduced ejection fractions (HFrEF) can be treated pharmacologically. Myocardial titin filament stiffening, endothelial dysfunction, and skeletal muscle (SKM) myopathy are suspected to contribute to HFpEF genesis. We previously described small molecules interfering with MuRF1 target recognition thereby attenuating SKM myopathy and dysfunction in HFrEF animal models. The aim of the present study was to test the efficacy of one small molecule (MyoMed-205) in HFpEF and to describe molecular changes elicited by MyoMed-205. - Methods Twenty-week-old female obese ZSF1 rats received the MuRF1 inhibitor MyoMed-205 for 12 weeks; a comparison was made to age-matched untreated ZSF1-lean (healthy) and obese rats as controls. LV (left ventricle) unction was assessed by echocardiography and by invasive haemodynamic measurements until week 32. At week 32, SKM and endothelial functions were measured and tissues collected for molecular analyses. Proteome-wide analysis followed by WBs and RT-PCR was applied to identify specific genes and affected molecular pathways. MuRF1 knockout mice (MuRF1-KO) SKM tissues were included to validate MuRF1-specificity. - Results By week 32, untreated obese rats had normal LV ejection fraction but augmented E/e′ ratios and increased end diastolic pressure and myocardial fibrosis, all typical features of HFpEF. Furthermore, SKM myopathy (both atrophy and force loss) and endothelial dysfunction were detected. In contrast, MyoMed-205 treated rats had markedly improved diastolic function, less myocardial fibrosis, reduced SKM myopathy, and increased SKM function. SKM extracts from MyoMed-205 treated rats had reduced MuRF1 content and lowered total muscle protein ubiquitination. In addition, proteomic profiling identified eight proteins to respond specifically to MyoMed-205 treatment. Five out of these eight proteins are involved in mitochondrial metabolism, dynamics, or autophagy. Consistent with the mitochondria being a MyoMed-205 target, the synthesis of mitochondrial respiratory chain complexes I + II was increased in treated rats. MuRF1-KO SKM controls also had elevated mitochondrial complex I and II activities, also suggesting mitochondrial activity regulation by MuRF1. - Conclusions MyoMed-205 improved myocardial diastolic function and prevented SKM atrophy/function in the ZSF1 animal model of HFpEF. Mechanistically, SKM benefited from an attenuated ubiquitin proteasome system and augmented synthesis/activity of proteins of the mitochondrial respiratory chain while the myocardium seemed to benefit from reduced titin modifications and fibrosis.

No description available.

Heart failure with preserved ejection fraction has its main pathophysiology in the diastolic dysfunction which is characterized by increased filling pressures. This can be discovered during a routinely performed echocardiographic examination. In 2016 the American Society of Echocardiography published a recommendation to simplify the assessment of diastolic dysfunction. Whether or not these recommendations have simplified the gradings is questionable. Left atrial strain has been shown to decrease in the absent of diastolic dysfunction and 3D echocardiographic volume measurements of the left atrium has been showing more accurate volumes of the heart compared to 2D-measurements. A quantitative study was therefore made to compare the results from the recommended algorithm with the two methods - left atrial strain and 3D-measurements of the left atrium volume. A total of 138 women and men were included with the data collected both prospective and retrospective. The aim with this quantitative study was to examine if LA-strain and 3D volume measurements of the left atrium can be useful parameters to use in detecting diastolic dysfunction in future recommendations. The result showed significant differences (p<0.05) in LA-strain between normal diastolic function and grade 2 and -3. Also, between grade 1 and grade 2- and 3. Between undetermined diastolic function there was a statistical difference with grade 2- and 3. LA-strain showed a significant negative correlation between E/é and 2D. LA-strain and 3D-measurements of the left atrium can be useful tools in the next recommendations of grading diastolic dysfunction.

Cardiovascular diseases are among the leading causes of deaths worldwide, but the fluid mechanics of many of these conditions and the devices used to treat them are only partially understood. This goal of this dissertation was to develop new experimental techniques that would enable translational research into two of these conditions. The first set of experiments examined <i>in-vitro</i> the changes in Wall Shear Stress (WSS) and Oscillatory Shear Index (OSI) caused by the implantation of coronary stents into the arteries of the heart using Particle Image Velocimetry. These experiments featured one-to-one scaling, commercial stents, and realistic flow and pressure waveforms, and are believed to be the most physiologically accurate stent experiments to date. This work revealed distinct differences in WSS and OSI between the different stent designs tested, and showed that changes in implantation configuration also affected these hemodynamic parameters. Also, the production of vortices near the stent struts during flow reversal was noted, and an inverse correlation between WSS and OSI was described. The second set of experiments investigated Left Ventricular Diastolic Dysfunction (LVDD) using phase contrast magnetic resonance imaging (pcMRI). Using this technique, ten patients with and without LVDD were scanned and a 2D portrait of blood flow through their heart was obtained. To augment this data, pressure fields were calculated from the velocity data using an omni-directional pressure integration scheme coupled with a proper-orthogonal decomposition-based smoothing. This technique was selected from a variety of methods from the literature based on an extensive error analysis and comparison. With this coupled information, it was observed that healthy patients exhibited different flow patterns than diseased patients, and had stronger pressure differences during early filling. In particular, the ratio of early filling pressure to late filling pressure was a statistically significant predictor of diastolic dysfunction. Based on these observations, a novel hypothesis was presented that related the motion of the heart walls to the observed flow patterns and pressure gradients, which may explain the differences observed clinically between healthy and diseased patients. / Ph. D.

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome associated with a high morbidity and mortality rate. Leucine supplementation has been demonstrated to attenuate cardiac dysfunction in animal models of cachexia and heart failure with reduced ejection fraction (HFrEF). So far, no data exist on leucine supplementation on cardiac function in HFpEF. Thus, the current study aimed to investigate the effect of leucine supplementation on myocardial function and key signaling pathways in an established HFpEF rat model. Female ZSF1 rats were randomized into three groups: Control (untreated lean rats), HFpEF (untreated obese rats), and HFpEF_Leu (obese rats receiving standard chow enriched with 3% leucine). Leucine supplementation started at 20 weeks of age after an established HFpEF was confirmed in obese rats. In all animals, cardiac function was assessed by echocardiography at baseline and throughout the experiment. At the age of 32 weeks, hemodynamics were measured invasively, and myocardial tissue was collected for assessment of mitochondrial function and for histological and molecular analyses. Leucine had already improved diastolic function after 4 weeks of treatment. This was accompanied by improved hemodynamics and reduced stiffness, as well as by reduced left ventricular fibrosis and hypertrophy. Cardiac mitochondrial respiratory function was improved by leucine without alteration of the cardiac mitochondrial content. Lastly, leucine supplementation suppressed the expression and nuclear localization of HDAC4 and was associated with Protein kinase A activation. Our data show that leucine supplementation improves diastolic function and decreases remodeling processes in a rat model of HFpEF. Beneficial effects were associated with HDAC4/TGF-β1/Collagenase downregulation and indicate a potential use in the treatment of HFpEF.

No description available.

No description available.

名古屋大学博士学位論文 学位の種類 : 博士(医学)(論文) 学位授与年月日:平成4年7月20日 淺田義正氏の博士論文として提出された

No description available.

No description available.